Study population characteristics
| Eligible patients (n) | 104 |
| Age (median ±SD) | 67±14.8 |
| Race | |
| Black (n, %) | 92 (88.5%) |
| White (n, %) | 4 (3.8%) |
| Other (n, %) | 8 (7.7%) |
| Gender | |
| Male (n, %) | 60 (57.7%) |
| Female (n, %) | 44 (42.3%) |
| Body mass index | |
| <18.5 (n, %) | 3 (2.9%) |
| 18.5–24.9 (n, %) | 19 (18.3%) |
| 25–29.9 (n, %) | 30 (28.8%) |
| 30–39.9 (n, %) | 34 (32.7%) |
| >40 (n, %) | 16 (15.4%) |
| Unknown | 2 (1.9%) |
| Medical history | |
| Hypertension (n, %) | 78 (75.0%) |
| Diabetes (n, %) | 35 (33.7%) |
| Chronic kidney disease (n, %) | 25 (24.0%) |
| Lung disease (n, %) | 29 (27.9%) |
| On home oxygen (n, %) | 9 (8.7%) |
| Heart disease (n, %) | 35 (33.7%) |
| Oncological (n, %) | 7 (6.7%) |
| Admission labs | |
| SARS-CoV-2 lab confirmed (n, %) | 89 (83.2%) |
| SpO2% (median±SD) | 93%±10.7% |
| CRP—mg/L (median ±SD) | 156±112 |
| CPK—units/L (median ±SD) | 243±859 |
| LDH—units/L (median ±SD) | 519±481 |
| Ferritin—ng/mL (median ±SD) | 719±1594 |
| Troponin—ng/L (median ±SD) | 34±597.6 |
| Leucocyte count—10ˆ9/L (median ±SD) | 8950±5000 |
| Lymphocyte count—10ˆ9/L (median ±SD) | 0.9±0.51 |
| D-dimer—mg/L (median ±SD) | 2.0±12.8 |
| PTT—s (median ±SD) | 30.8±20.5 |
| PT—s (median ±SD) | 11.5±11.4 |
| INR (median±SD) | 1.1±1.3 |
| Radiographic pulmonary findings | |
| Multifocal infiltrates (n, %) | 85 (81.7%) |
| Focal infiltrates (n, %) | 10 (9.6%) |
| Normal (n, %) | 8 (7.7%) |
CPK, creatine phosphokinase; CRP, C reactive protein; INR, international normalised ratio; LDH, lactate dehydrogenase; PT, prothrombin time; PTT, partial thromboplastin time.